Screener
Pfizer PFE Restructuring charges and certain acquisition-related costs
Restructuring charges and certain acquisition-related costs at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept pfe:RestructuringChargesAndAcquisitionRelatedCosts.
The source filing: Pfizer’s 8-K, filed August 4, 2026. Open the filing →
- Filed
- Aug 4, 2026, 7:02 AM EDT
- Accession
- 0000078003-26-000094
FAQ
- What is Pfizer's restructuring charges and certain acquisition-related costs?
- Pfizer (PFE) reported restructuring charges and certain acquisition-related costs of $457M in Q2 2026.
- How has Pfizer's restructuring charges and certain acquisition-related costs changed year-over-year?
- Pfizer's restructuring charges and certain acquisition-related costs increased by 2638.9% year-over-year, from -$18M to $457M.
- What is the long-term trend for Pfizer's restructuring charges and certain acquisition-related costs?
- Over 4 years (2021 to 2025), Pfizer's restructuring charges and certain acquisition-related costs has grown at a 17.9% compound annual growth rate (CAGR), from $802M to $1.55B.
- What does restructuring charges and certain acquisition-related costs mean?
- Non-recurring charges associated with organizational restructuring, workforce reductions, facility consolidations, and integration costs following business acquisitions. These items are typically excluded from core operating performance metrics to show underlying business trends.
Ask your AI about Pfizer's restructuring charges and certain acquisition-related costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude